Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib

Am J Hematol. 2021 May 1;96(5):E137-E140. doi: 10.1002/ajh.26109. Epub 2021 Feb 11.

Authors

Preetesh Jain¹, Rashmi Kanagal-Shamanna², Shaojun Zhang³, Chi Young Ok², Lucy Navsaria¹, Loretta Nastoupil¹, Hun Ju Lee¹, Guilin Tang², C Cameron Yin², Maria Badillo¹, Ranjit Nair¹, Shaoying Li², Keyur M Patel², Christopher Flowers¹, Francisco Vega², Linghua Wang³, Michael L Wang¹

Affiliations

¹ Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
² Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
³ Department of Hemato-pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

PMID: 33491779
DOI: 10.1002/ajh.26109

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Agents / adverse effects
Antineoplastic Agents / therapeutic use*
Benzamides / adverse effects
Benzamides / therapeutic use*
Combined Modality Therapy
Disease Progression
Drug Substitution
Exome Sequencing
Follow-Up Studies
Humans
Immunotherapy, Adoptive
Kaplan-Meier Estimate
Lymphoma, Mantle-Cell / drug therapy*
Lymphoma, Mantle-Cell / genetics
Lymphoma, Mantle-Cell / therapy
Mutation
Protein Kinase Inhibitors / adverse effects
Protein Kinase Inhibitors / therapeutic use*
Pyrazines / adverse effects
Pyrazines / therapeutic use*
Recurrence
Salvage Therapy
Sample Size
Treatment Outcome
Withholding Treatment

Substances

Antineoplastic Agents
Benzamides
Protein Kinase Inhibitors
Pyrazines
acalabrutinib